CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 7 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,511,805 | +138.3% | 33,307 | +194.7% | 0.06% | +141.7% |
Q2 2023 | $634,438 | -88.6% | 11,301 | -90.8% | 0.02% | -89.6% |
Q1 2023 | $5,543,344 | +147.1% | 122,559 | +122.1% | 0.23% | +94.1% |
Q4 2022 | $2,243,352 | +463.7% | 55,187 | +770.0% | 0.12% | +600.0% |
Q1 2022 | $398,000 | +24.4% | 6,343 | +121.4% | 0.02% | -26.1% |
Q3 2021 | $320,000 | -50.5% | 2,865 | -45.9% | 0.02% | -61.7% |
Q1 2021 | $646,000 | – | 5,300 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |